Updated Public Statement of the HMPC on HMPs containing Estragole

Recommendation
18-20 November 2025
Heidelberg, Germany
GMP and FDA Compliance in Pharmaceutical Development and IMP Manufacturing
In 2005, the HMPC prepared the "Public statement on the use of herbal medicinal products containing estragole". There are many plants (including their preparations) which contain estragole, sometimes in particurlarly high amounts, like, for example, Foeniculum vulgare Mill. (Fennel) and Pimpinella anisum L. (Anise).
Now, several footnotes were added in Table 1 (Section 1.1) of the document regarding the provided examples of estragole-containing plants, stating the following:
- "Compilation originating mainly from the food sector, that is partially based on older publications whose cited original data are not (completely) publicly available anymore. The list not exhaustive."
- "The actual relevance for medicinal products should be cross-checked with the data provided in respective assessment reports for EU herbal monographs and/or recent scientific literature relevant for specific substances/preparations in question."
- "Plant with currently known use as active substance or excipient in medicinal products and relevant amount of estragole in the essential oil." (related to bitter fennel, sweet fennel, star anise and aniseed)
More information is available in HMPCs Public statement on the use of herbal medicinal products containing estragole.
Related GMP News
30.01.2025FDA seeks Feedback on Opiate Alkaloid Content of Poppy Seeds
30.01.2025Ensuring Microbiological Quality of Herbal Products
30.01.2025Research with Recreational Cannabis in Germany - Which Agency is Responsible?
15.10.2024Real-World Data Requirements for Herbal Medicinal Products
01.08.2024USP Cannabis Monograph
01.08.2024FDA issues Warning Letters for Selling Products containing Delta-8 THC